证券日报网讯 1月9日，海尔生物在互动平台回答投资者提问时表示，科技自立自强带动行业向国产化 发展，进一步拓宽了公司的发展空间，公司四大产业的市场竞争力加速提升。除优势的低温存储产业份 额持续提升外，截至2025年上半年，根据国内各主要招标网公开数据和第三方招标数据统计，公司血浆 采集方案市占率超过50%，自动化用药市场份额跻身行业前三，科研仪器国内市场占有率继续突破，其 中总有机碳分析仪和紫外分光光度计分列国产品牌第一、第二，离心系列市场份额跻身行业品牌前十， 6月生物安全柜跃升至全国第一、培养系列保持国产第一份额；此外，经初步市场调查统计，公司三大 低温产品线在海外25个国家市场份额居首位。 ...

Core Viewpoint - The company has signed a share transfer intention agreement with Shanghai Youke Instrument Co., Ltd. to acquire 35% equity for 61.25 million yuan, valuing the target company at 175 million yuan, making Shanghai Youke a subsidiary post-investment [1]. Group 1: Investment Rationale - The investment in Shanghai Youke is expected to significantly enhance the company's laboratory product line, addressing existing gaps and enabling a one-stop procurement model through bundled sales of reagents and instruments, creating synergistic effects [2]. - Leveraging Aladdin's established customer base, channel resources, e-commerce platforms, and warehousing capabilities, the investment aims to accelerate Shanghai Youke's growth and enhance equity value [2]. Group 2: Valuation and Financial Projections - The total assets of Shanghai Youke are projected at 162 million yuan, with net assets of 96 million yuan, revenue of 102 million yuan, and net profit of 22.48 million yuan for 2024. The investment's valuation corresponds to a PE ratio of approximately 7.8 times and a PB ratio of about 1.8 times [3]. - The company is actively pursuing external acquisitions to expand its business scope, having completed several significant transactions in 2024, including acquisitions of Yuan Ye Biology and shares in Shanghai Yamei, reinforcing its dual growth strategy of "internal growth + external expansion" [3]. - Revenue forecasts for 2025-2027 are 649 million yuan, 860 million yuan, and 964 million yuan, with corresponding net profits of 96 million yuan, 146 million yuan, and 170 million yuan, leading to diluted EPS of 0.29 yuan, 0.44 yuan, and 0.51 yuan, with PE ratios of 44.19, 29.12, and 24.99 respectively [3].

Core Viewpoint - Aladdin plans to acquire 35% equity in Youke for a cash payment of 61.25 million yuan, which will enhance its product line in laboratory general analytical instruments and improve customer procurement convenience and loyalty [1][2]. Group 1 - Aladdin has signed a share transfer intention agreement with Shanghai Youke Instrument Co., Ltd. for the acquisition [2]. - The investment will make Youke a subsidiary of Aladdin, allowing for better integration of resources [2]. - Youke specializes in the research, production, sales, and service of laboratory general analytical instruments, and is a supplier of "Made in China" analytical instruments in the international market [2]. Group 2 - The main products of Youke include UV spectrophotometers, pH meters, conductivity meters, biological microscopes, and gas chromatography instruments [2]. - Aladdin aims to leverage its customer resources, channel resources, e-commerce platform resources, and warehousing resources both domestically and internationally to empower Youke [2].

Investment Rating - The report assigns a "Buy" rating for Aladdin (688179) based on its strong potential for growth and strategic acquisitions [10]. Core Insights - The investment in Shanghai Youke is expected to enhance Aladdin's product line in laboratory instruments, allowing for bundled sales of reagents and instruments, thus creating a synergistic effect [2]. - The valuation for the stake in Shanghai Youke is considered reasonable, with a PE ratio of approximately 7.8 times and a PB ratio of about 1.8 times, indicating a solid investment opportunity [3]. - Aladdin's revenue and profit forecasts for 2025-2027 show significant growth, with projected revenues of 6.49 billion, 8.60 billion, and 9.64 billion respectively, and net profits of 0.96 billion, 1.46 billion, and 1.70 billion [3]. Financial Summary - Total revenue for 2023 is reported at 403 million, with a year-on-year growth rate of 6.6%. This is expected to increase to 534 million in 2024, representing a growth rate of 32.4% [4]. - The net profit for 2023 is 86 million, with a projected decline of 7.5% year-on-year, but is expected to recover to 99 million in 2024, reflecting a growth of 15.1% [4]. - The gross margin is forecasted to remain stable around 62.6% to 62.9% from 2025 to 2027, indicating strong operational efficiency [4].

Core Viewpoint - The National Certification and Accreditation Administration (NCAA) has released seven new industry standards for the verification and evaluation of domestically produced testing instruments, aimed at promoting the localization and quality enhancement of mid-to-high-end testing and inspection equipment in China [2][3]. Summary by Relevant Sections - **New Standards Released**: In November 2025, NCAA published the "Guidelines for Verification and Evaluation of Domestic Testing Instruments" covering various devices including liquid chromatographs, liquid chromatography-mass spectrometry systems, ion chromatographs, UV spectrophotometers, capillary electrophoresis instruments, tire-coupled road simulation test machines, and flexible traffic targets [2][3][4]. - **Implementation Timeline**: The new standards were approved on November 1, 2025, and are set to be implemented starting January 1, 2026 [4]. - **Previous Standards**: This is not the first set of guidelines issued by NCAA; five standards were previously released in May 2024, which included gas chromatographs, atomic absorption spectrophotometers, AC power chassis dynamometers, flexible target-driven platform vehicles, and hydrogen fuel cell stack testing equipment [4][5][6][7]. - **Industry Impact**: The establishment of these guidelines is a crucial step towards the high-quality development of domestic testing instruments. It is expected to promote the standardization and normalization of the domestic testing instrument industry, fostering a competitive environment among companies and driving the industry to new heights [8].

Core Viewpoint - Haier Biomedical has shown significant performance recovery in Q3 2025, driven by strong revenue growth and improved profitability, indicating a positive trend in the life sciences and medical device sectors as they transition towards international expansion and technological innovation [1][2]. Group 1: Financial Performance - In Q3 2025, Haier Biomedical achieved a revenue of 566 million yuan, representing a year-on-year increase of 1.24% and a quarter-on-quarter increase of 11.68% [1]. - The net profit attributable to shareholders reached 55.65 million yuan, with a quarter-on-quarter growth exceeding 70% [1]. - The non-recurring net profit was 49.99 million yuan, showing a quarter-on-quarter increase of over 100% [1]. Group 2: Industry Trends - The life sciences sector is entering a new phase of valuation recovery and industrial upgrading after a decade of development, supported by supply clearing, demand recovery, and accelerated domestic substitution [2]. - Haier Biomedical's performance recovery is attributed to revenue growth, business structure upgrades, and enhanced product competitiveness [2]. Group 3: Business Segments - The recovery in Q3 is supported by four key industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, which have begun to show stable performance [3]. - New industries, particularly smart medication and blood technology, have demonstrated significant growth, contributing to approximately 48% of total revenue [3]. - The smart medication segment has established itself among the top three in the automated medication market by addressing hospital drug management challenges [3]. Group 4: Market Position and Innovation - The low-temperature storage segment continues to maintain a leading market share in China, with steady growth in revenue [4]. - Haier Biomedical's commitment to technological innovation is evident in its AI integration and the establishment of a multi-layered AI foundation, enhancing its product offerings and market responsiveness [5][6]. - The company reported a 20.18% year-on-year increase in overseas market revenue, reaching 634 million yuan, with successful localization strategies implemented in 18 countries [6].

Core Insights - The inquiry value of the Instrument Information Network increased by 39% quarter-on-quarter in Q3 2025, with stable demand in the top 10 categories, and a slight decrease in the proportion of domestic demand [2][4][7] Inquiry Value and Demand Categories - In Q3 2025, the overall inquiry value increased by 39%, with industrial enterprises accounting for the largest share, followed by universities. Industrial enterprises had a higher volume of inquiries, while universities had a higher value per inquiry [4][6] - The top 10 categories of instruments remained largely unchanged from Q2, indicating stable demand for major instrument types. The categories included gas chromatographs, infrared spectrometers, and centrifuges among others [6][4] Domestic vs. Imported Demand - The proportion of inquiries specifying domestic products was 16%, while imported products accounted for 6%. There was a 3 percentage point decrease in the demand for domestic products and a corresponding increase for imported products, reflecting a temporary fluctuation within the broader trend of domestic substitution [7][4] Offline Activities and Market Engagement - The Q3 buyer service team of the Instrument Information Network organized a "Ten Thousand Miles" event in Shijiazhuang, collaborating with local partners to engage with pharmaceutical companies, universities, and testing institutions. This initiative aimed to understand the application and challenges of domestic testing equipment [10][9] Membership and Platform Services - The Instrument Information Network offers a membership service called "Yixin Tong," which provides manufacturers with dedicated websites and extensive exposure to over 25 million professional users, enhancing product visibility and brand empowerment [13][14]

Investment Rating - The report maintains a "Recommended" rating for Haier Biomedical (688139) [1] Core Views - The company reported a 2.27% decline in revenue for H1 2025, totaling 1.196 billion yuan, and a 39.09% drop in net profit to 143 million yuan, primarily due to external factors and strategic investments [1][5] - New industries are showing growth, with their revenue share increasing to 47%, reflecting a 7.27% year-on-year growth, particularly in laboratory solutions and smart medication [5] - The overseas business is performing strongly, with a 30.17% increase in overseas revenue to 427 million yuan in H1 2025, while domestic revenue fell by 14.64% to 761 million yuan [5] Financial Summary - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 2,284 million, 2,630 million, 3,061 million, and 3,464 million yuan respectively, with expected growth rates of 0.1%, 15.2%, 16.4%, and 13.2% [1][6] - Net profit projections for the same years are 367 million, 423 million, 508 million, and 585 million yuan, with growth rates of -9.7%, 15.4%, 20.1%, and 15.1% [1][6] - The company’s earnings per share (EPS) is projected to increase from 1.15 yuan in 2024A to 1.84 yuan in 2027E [6]

Core Viewpoint - Haier Biomedical's performance in the first half of the year was under pressure due to external factors, new capacity ramp-up, and strategic investments, but the overall performance is expected to improve with industry recovery and accelerated innovation [1] Group 1: Financial Performance - The company's revenue and profit in the second quarter were at their lowest for the year, with expectations for improved profitability in the third and fourth quarters [1] - New industries accounted for 47% of total revenue, showing a year-on-year growth of 7.27%, with smart medication, blood technology, and laboratory solutions each contributing approximately 11%, 11%, and 17% to total revenue respectively [2] Group 2: Market Position - Haier Biomedical's plasma collection solutions have a market share exceeding 50%, and its automated medication market share ranks among the top three in the industry [2] - The company has achieved leading positions in the domestic market for total organic carbon analyzers and UV spectrophotometers, with its biological safety cabinets ranking first nationally [2] Group 3: Overseas Business - The company achieved overseas revenue of 427 million yuan, a year-on-year increase of 30.17%, with the second quarter marking the highest quarterly revenue and growth rate in 2023 [3] - Products and solutions are applied in over 150 countries, with localized operations established in 17 countries, and three low-temperature product lines leading in market share in 25 countries [3] Group 4: AI Development - The company is enhancing its AI infrastructure with a multi-layered architecture, integrating AI technology with life sciences and medical innovation [4] - A foundational AI model, "Yingkang Brain," has been developed, focusing on various industry fields, resulting in 17 specialized AI clusters [4] - The integration of AI into medical decision-making and research experiments is being realized through automated solutions and hardware systems, creating an efficient collaboration of data, devices, and scenarios [4]

Core Insights - The company experienced a decline in performance in the first half of 2025, with revenue of 1.196 billion yuan (down 2.27% year-on-year) and a net profit of 143 million yuan (down 39.09% year-on-year) due to various factors including global market volatility and strategic investments [1] - The domestic market faced short-term pressure, while the overseas market showed strong performance with revenue of 427 million yuan (up 30.17% year-on-year) [1] - The life sciences segment generated revenue of 599 million yuan, with low-temperature storage business showing signs of recovery and laboratory solutions gaining market share [2] - The medical innovation segment achieved revenue of 589 million yuan, with significant growth in smart medication and blood technology, contributing to 47% of total revenue [3] Financial Performance - In H1 2025, the company's gross margin was 46.28% (down 1.99 percentage points year-on-year) and net margin was 12.31% (down 7.24 percentage points year-on-year) [1] - The company anticipates a recovery in profitability in H2 2025, supported by a 38% increase in the domestic market project pipeline and substantial growth in medical channels [1] Business Segments - The low-temperature storage business declined by 9.9% year-on-year but showed a recovery trend with a 16.73% increase compared to H2 2024 [2] - The smart medication segment grew by approximately 6% year-on-year, with expectations for high double-digit growth for the full year [3] - Blood technology revenue increased by 19% year-on-year, significantly outperforming the industry average [3] Strategic Outlook - The company is transitioning from a low-temperature storage equipment provider to a life sciences and medical innovation platform, with rapid growth in new industries [4] - Profit forecasts for 2025-2027 are maintained at 408 million, 481 million, and 562 million yuan respectively, with corresponding EPS of 1.28, 1.51, and 1.77 yuan [4]